Clinical Trials Market To Witness Massive Growth

Clinical Trials Industry Overview

The global clinical trials market was valued at USD 80.7 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030. This growth is driven by multiple factors, including technological advancements, the rising prevalence of chronic diseases, and the increased demand for personalized medicine. The market saw a significant surge in 2020 due to the COVID-19 pandemic, which spurred investments in drug development aimed at alleviating the burden on patients. Both virtual and traditional clinical trials saw growth during this period, as companies scrambled to develop treatments for COVID-19. An example of this was the collaboration between Synairgen plc and Parexel in 2020, where they conducted a Phase III study of Interferon-beta (IFN-beta) treatment for COVID-19.

The pandemic also led to a shift in how clinical trials are conducted. Traditional research models were adapted to accommodate virtual and decentralized trials. Regulatory agencies such as the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China’s National Medical Products Administration issued various guidelines to support the implementation of these new approaches. These guidelines facilitated the use of virtual services and decentralized models, enabling trials to continue despite lockdowns and restrictions. This shift towards virtual clinical trials, combined with the demand for innovative treatment solutions, has accelerated the adoption of fast-track clinical trials, opening new opportunities in the market.

In addition to the impact of the pandemic, government support has also played a critical role in the market's growth. For example, the World Health Organization (WHO) launched the Solidarity trial during the pandemic, an international clinical trial aimed at finding effective treatments for COVID-19. This trial compared several treatment options against the standard care protocols to evaluate their effectiveness against the virus. Furthermore, in May 2020, the WHO initiated an international alliance to develop multiple candidate vaccines, calling it the Solidarity trial for vaccines. These initiatives, along with continued government backing for clinical trials, further support the market's growth potential, as they drive research efforts and bring new treatments to market.

Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market

Regional Insights:

North America Market Share and Growth

North America held a dominant share of 50.3% of the global clinical trials market in 2023 and is expected to maintain its leadership throughout the forecast period.
This growth can be attributed to a significant increase in research and development (R&D) investments and the adoption of innovative technologies in clinical trials.
For example, market players like IQVIA and PRA Health Sciences are implementing virtual services across various stages of clinical trials, which is anticipated to further accelerate market growth in the region.
Additionally, government support in the U.S. is expected to boost demand for clinical trials.
In March 2020, the FDA launched the Coronavirus Treatment Acceleration Program (CTAP), aimed at accelerating the development of therapies for COVID-19. The program utilizes all available resources to quickly bring novel treatments to patients, while also assessing their safety and efficacy.

Asia Pacific Market Growth

The Asia Pacific region is projected to experience the fastest growth in the clinical trials market over the forecast period.
One of the main drivers for this growth is the availability of a large patient pool, which allows for easier recruitment and faster trial execution.
The global COVID-19 pandemic has also contributed significantly to this growth.
Asia Pacific’s largest biotech CRO, Novotech, has reported a rise in demand from biotechnology sponsors for clinical trials due to the region’s ability to offer high-quality services with quick turnaround times.
As a result, many biotechnology firms are increasingly choosing the APAC region to conduct their COVID-19 trials, benefiting from a large patient base and accelerated procedures.

Indian Clinical Trials Market

The Indian clinical trials market is expected to grow at a CAGR of 8.3% during the forecast period.
Key factors driving this growth include the globalization of clinical trials, the adoption of new technologies in clinical research, and the increasing prevalence of diseases that require research and development.
Additionally, India is emerging as a preferred location for outsourcing clinical trials due to cost advantages, a large and diverse patient population, and the country’s growing infrastructure for conducting clinical research.

Browse through Grand View Research's Healthcare IT Industry Research Reports.

The global gene therapy market size was estimated at USD 5.54 billion in 2023 and is projected to grow at a CAGR of 18.88% from 2024 to 2030.
The global burial insurance market size was valued at USD 279.78 billion in 2023 and is projected to grow at a CAGR of 5.6% from 2024 to 2030.

Key Clinical Trials Company Insights

The global clinical trials market is highly competitive. Some of the players operating in the market include IQVIA, PAREXEL International Corporation, Pharmaceutical Product Development, LLC, and Charles River Laboratory. The major factor influencing the competitive nature is the quick adoption of advanced technology for improved healthcare. In addition, to retain their market share and expand their product portfolio, major players are often involved in mergers and acquisitions as well as initiating new product launches.

Key Clinical Trials Companies: